Lamivudine resistance mutations in European patients with hepatitis B and patients co‐infected with HIV and hepatitis B

Abstract

Evaluation of resistance pattern in patients with chronic hepatitis B. Retrospective study of hepatitis B virus (HBV) resistance mutations in patients found viraemic after first-line treatment. HBV viral load was determined by a real-time polymerase chain reaction and the substitutions in HBV-DNA were studied by polymerase sequencing test. First line treatment had failed in 12 out of 33 patients (36%) receiving anti-HBV drugs. The 12 patients with persistent viraemia were all lamivudine (LAM) experienced and 7 had a polymerase sequencing test available. LAM substitution mutations L180M + M204V/I were found in six out of seven cases, with an accompanying V173L mutation in three cases. These mutations were also related with changes in HBsAg. The use of potent drugs in the first line anti-HBV therapy may reduce the resistance mutations in the future.

High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China

“…The prevalence in 3TC monotreatment is about 40–77.8% among those who receive 3TC treatment for 1 year or longer [22, 23]. 3TC resistance may occur in a small proportion of patients during 3TC plus TDF treatment [24, 25]. In this study, a very high prevalence (76.4%) of 3TC resistance was found in patients on HAART, including 3TC plus TDF.…”

“…However, certain co-infected patients exhibit incomplete viral suppression, with persistent, and sometimes transient bouts of HBV replication [27, 28]. Up to 17% of patients developed virological breakthrough during 3TC plus TDF treatment [24, 25, 29]. In this study, 8.8% of patients on HAART developed virological breakthrough.…”

High Incidence of Lamivudine-Resistance-Associated Vaccine-Escape HBV Mutants among HIV-Coinfected Patients on Prolonged Antiretroviral Therapy

“…Furthermore, the signs of liver damage were detected among these HIV-coinfected patients harbouring 3TC-resistant triple HBV mutants as indicated by the elevated ALT level and the presence of cccDNA in serum. Moreover, to the best of our knowledge this study is the first which adds to the information regarding 3TC-resistance among the HIV-HBV-coinfected Indian population in the reports available from different parts of the world [20][21][22][23][24][25][26][27][28][29].…”